India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving Medicines at much cheaper cost than by obtaining the medicine from...
More »SEARCH RESULT
Cheap generics no panacea for India's poorest
-Reuters Cheap generic drugs were meant to change the life of Nandakhu Nissar, whose mouth is swollen by a cancerous tumour. But the cashless and hungry 55-year-old sleeps on a pavement staring up at the windows of Mumbai's biggest cancer hospital. "What is a generic drug?" shrugs Nissar, who has travelled over 1,500 kms (900 miles) from his home in the hope of treatment. "I have borrowed money from friends and relatives...
More »3 years of RTI in J&K-Dr Raja Muzaffar Bhat
Today is 20th March and it was this day in 2009 when the new form of Right to Information Act (RTI Act) was enacted in J&K by Omar Abdullah led Government soon after coming to power. Prior to 2009 we had an RTI law passed by PDP Congress coalition Government headed by Mufti Mohammad Syeed in 2004 (J&K RTI Act 2004). The 2004 version of RTI Act was much weaker...
More »‘Focus on nutrition of children with HIV’: child rights commission by Sonal Matharu
National AIDS Control Programme urged to move beyond medicine-centric approach The government programmes for children suffering from HIV/AIDS should move from medicine-centric approach to include nutrition and preventive care, the National Commission for Protection of Child Rights (NCPCR) has recommended. In its recently released report ‘Rights and entitlements of children affected and infected by HIV/AIDS 2010-11’, the organisation also advocated provisions for issuing BPL cards to children who have lost their...
More »A historic move to make drugs affordable-G Ananthakrishnan
India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »